Skip to main content

Letter

Letter Requesting Briefing on Reporting Requirements for Generic Drugs


03.06.20

Excerpt: “Since this provision in FDARA was passed into law, we have heard about additional ways that some drug manufacturers may be manipulating the market to harm competition and raise prices.  A complaint filed by the Attorney General of Connecticut and a 44-state coalition in May 2019 details instances where generic manufacturers allegedly exited the market temporarily to suppress competition and fix prices,” bipartisan committee leaders wrote.

CLICK HERE to read the letter.

Letter